Implementation of quality indicators for ovarian cancer in gynecological cancer centers certified by the German Cancer Society (DKG)
PURPOSE: Since 2008, the German Cancer Society (DKG) has certified gynecological cancer centers to ensure high-quality care with guideline-based quality indicators (QI) as a core component. This article summarizes the German development and update of ovarian cancer (OC) QI based on the current S3-guideline (2026) and presents their performance. METHODS: This was a retrospective, descriptive, observational analysis of aggregated annual-report data for treatment years 2019-2024; no inferential statistics were performed. QI were derived from strong S3-guideline recommendations through a structured multi-step process. Experts identified potential QI according to standardized criteria (including feasibility and impact on care). QI required ≥ 75% agreement. Since 2017, each tumor entity has been limited to five key QI in the certification dataset. RESULTS: Eight guideline-derived QI are currently defined for OC, five QI are included in the certification program. In 2024, 184 certified centers treated 4.951 primary OC cases. At center level, the predefined target values were met for surgical staging (93.5% of centers; target ≥ 40%), offering genetic testing (97.8%; target ≥ 70%), complete macroscopic resection (99.5%; target ≥ 30%), and surgery by a gynecologic oncologist (98.9%; target ≥ 80%). All centers (100%) met plausibility limits for first-line chemotherapy (75.1% of advanced-stage patients). At patient level, pooled adherence rates improved over time; the median rate of offering genetic testing rose from 61% (2019) to 84% (2024). Two QI were retired in 2021, and one QI is pending until further guideline updates. CONCLUSION: Guideline-based QI translate essential recommendations into measurable metrics, allowing objective assessment of quality. High and increasing adherence rates were observed in certified centers. These findings support the use of guideline-based QI for benchmarking and continuous quality improvement, although the observational design precludes causal attribution to certification.
Authors
- Martin J. Utzig (ORCID: https://orcid.org/0009-0003-1403-8827)
- Nina Pauly (ORCID: https://orcid.org/0000-0003-1726-8997)
- Patrik Pöschke
- Beyhan Ataseven (ORCID: https://orcid.org/0000-0002-2823-7590)
- Olaf Ortmann (ORCID: https://orcid.org/0000-0001-6238-3949)
- Matthias W. Beckmann (ORCID: https://orcid.org/0000-0002-8441-693X)
- Carla Emilia Schulmeyer (ORCID: https://orcid.org/0000-0002-1622-5250)
- Julius Emons (ORCID: https://orcid.org/0000-0002-2520-4443)
- Frederik A. Stuebs
- Birgit Klages
- Pauline Wimberger
Institutions
- German Cancer Research Center (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Bielefeld University (DE)
- Helmholtz-Zentrum Dresden-Rossendorf (DE)
- University Hospital Regensburg (DE)
- Universitätsklinikum Erlangen (DE)
- German Cancer Society (DE)
- Klinikum Lippe (DE)
- Klinikum Bielefeld (DE)
- Comprehensive Cancer Center Erlangen (DE)
- University Hospital Carl Gustav Carus (DE)
- Nationales Centrum für Tumorerkrankungen Dresden (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- German Cancer Research Center (DKFZ) Dresden (DE)
- German Cancer Consortium (DKTK) Dresden (DE)
- Technische Universität Dresden (DE)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1007/s00432-026-06644-0
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Andrew W. Mellon Foundation
- Deutsche Krebshilfe
- Universitätsklinikum Erlangen